SynopsisMetformin, marketed under the trade name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. The global Metformin Drugs market was valued at US$ 3784 million in 2023 and i.....
SynopsisMetformin, marketed under the trade name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. The global Metformin Hydrochloride Drugs market was valued at US$ 3784 million.....
SynopsisMetformin, marketed under the trade name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. The global Metformin Hydrochloride Tablet market was valued at US$ 3784 millio.....
SynopsisGlucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have .....
SynopsisTeduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. The global Glucagon-like Peptide-2 (GLP-2) Agonist market w.....
SynopsisTeduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. The global Teduglutide market was valued at US$ 751 million.....
SynopsisTeduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. The global Teduglutide Drugs market was valued at US$ 751 m.....
SynopsisGlatiramer is an immunomodulator medication currently used to treat multiple sclerosis. The global Glatiramer market was valued at US$ 1072 million in 2023 and is anticipated to reach US$ 597.1 million by 2030, witnessing a CAGR of -6.8% during the forec.....
SynopsisGlatiramer is an immunomodulator medication currently used to treat multiple sclerosis. The global Glatiramer Drugs market was valued at US$ 1072 million in 2023 and is anticipated to reach US$ 597.1 million by 2030, witnessing a CAGR of -6.8% during the.....
SynopsisGlatiramer acetate is an immunomodulator medication currently used to treat multiple sclerosis. The global Glatiramer Acetate market was valued at US$ 1072 million in 2023 and is anticipated to reach US$ 597.1 million by 2030, witnessing a CAGR of -6.8% .....
